Empress Therapeutics
Jason Park has extensive experience in the life sciences industry, with a focus on founding and growing innovative companies. Jason is the current Chief Executive Officer of Empress Therapeutics, a position they have held since July 2022. Prior to this, Jason was a Partner at Flagship Pioneering, where they played a key role in conceiving, creating, and growing life science companies. Jason was also the CEO and Co-Founder of Empress Therapeutics, as well as the COO and Co-Founder of Sonata Therapeutics. Before joining Flagship Pioneering, Jason worked as a Project Leader at The Boston Consulting Group, where they gained exposure in healthcare, technology, and strategy. Jason was also a member of the BCG Scientist Network. Jason's work at BCG included leading projects on various topics such as R&D, investment strategy, manufacturing, due diligence, and global health. Prior to BCG, they held positions at Carigent Therapeutics and co-founded Things Are Common, LLC.
Jason Park holds a Ph.D. degree in Biomedical Engineering from Yale University. Jason also attended Yale School of Management as a cross-registrant, where they studied Accounting, Finance, Competitive Strategy, and Venture Capital. Prior to that, they obtained a Master's degree in Engineering & Applied Science and a Bachelor's degree in Biomedical Engineering, both from Yale University.
Empress Therapeutics
Founded by Flagship Pioneering, Empress re-imagines the process of small molecule drug discovery. Our bioplatform harnesses the power of evolution, human molecular and genetic data, and artificial intelligence to focus on endogenous sources of inherently drug-like small molecules as a uniquely qualified source of potential drugs. Our mission is to generate transformative drug candidates that get to the clinic faster and cheaper, with a higher probability of success.